4164.SR
4164.SR
SA15HG521213
Nahdi Medical Co.
Loading chart...

Company Profile

Nahdi Medical Company, together with its subsidiaries, engages in the wholesale and retail trading of cosmetics, pharmaceutical, special and healthy foods, and medical equipment products in the Kingdom of Saudi Arabia and the United Arab Emirates. The company also offers mom and baby, beauty, and everyday essentials through retail and online stores. In addition, it operates Nahdi Care polyclinic; and provides virtual care services. Further, the company is involved in operating E-Pharmacist platform; and Nahdi Online, an online pharmacy. Additionally, it provides labor and IT consulting services. Nahdi Medical Company was incorporated in 1986 and is headquartered in Jeddah, the Kingdom of Saudi Arabia.

Related stocks

CLS.JO
CLS.JO • South Africa
Clicks Group Ltd
21,427 ZAc
3.04B USD 1Y -41%
4163.SR
4163.SR • Saudi Arabia
Aldawaa Medical Services Co.
34.7 SAR
785.49M USD 1Y -48.4%
DCP.JO
DCP.JO • South Africa
Dis-Chem Pharmacies Ltd
2,691 ZAc
1.4B USD 1Y -18.2%
3349.T
3349.T • Japan
COSMOS PHARMACEUTICAL CORP
6,392 JPY
3.2B USD 1Y -23.8%
9989.T
9989.T • Japan
SUNDRUG CO LTD
3,530 JPY
2.61B USD 1Y -16.5%
3549.T
3549.T • Japan
KUSURI NO AOKI HOLDINGS CO LTD
4,138 JPY
2.48B USD 1Y +12%
7649.T
7649.T • Japan
SUGI HOLDINGS CO.LTD.
1,227.5 JPY
2.89B USD 1Y -27.4%
603233.SS
603233.SS • China
DASHENLIN PHARMACEUTICAL GROUP
18.76 CNY
3.2B USD 1Y +12.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
23.3% p.a.
Max Drawdown (5Y)
-56.4%
Sharpe Ratio (5Y)
-0.66
Beta Factor
0.11
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Historical Stress Test: Maximum peak-to-trough drawdown of -56.4% in the extended horizon.
ende